Our robust clinical pipeline includes small molecule, biologic and cellular therapies for the treatment of cancer. The Athenex team continues to fuel the rapid expansion of this clinical pipeline now comprised of nine total IND’s.
Taken together, our clinical pipeline balances a range of therapeutic approaches for the treatment of cancer to enable us to improve the lives of cancer patients.
* Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline ** Collaboration with Eli Lilly and Company, makers of ramucirumab